tiprankstipranks
Advertisement
Advertisement

Angelalign forecasts sharp profit surge on clear aligner growth and operating leverage

Story Highlights
  • Angelalign expects 2025 net profit to jump sharply as clear aligner demand and China penetration drive revenue growth.
  • Operating leverage from prior investments and lower-than-expected costs underpin a strong profit rebound that may strengthen Angelalign’s market position.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Angelalign forecasts sharp profit surge on clear aligner growth and operating leverage

Claim 30% Off TipRanks

Angelalign Technology Inc. ( (HK:6699) ) has provided an update.

Angelalign Technology has issued a positive profit alert, saying it expects net profit for 2025 to rise to between USD24 million and USD30 million, up 140% to 200% from USD10 million in 2024. The improvement is driven by stronger global demand for its clear aligner products, greater penetration in China, operating leverage from prior investments, delayed ramp-up costs at non-China facilities, lower legal expenses in the period, and comparison with a 2024 base depressed by strategic spending.

The company highlighted that prior investments in localized sales and centralized functions are now delivering efficiency and scale benefits. While the figures are based on unaudited management accounts and may be adjusted, the anticipated profit surge underscores a significant rebound in profitability that could bolster investor confidence and reinforce Angelalign’s competitive position in the clear aligner market.

The most recent analyst rating on (HK:6699) stock is a Sell with a HK$66.00 price target. To see the full list of analyst forecasts on Angelalign Technology Inc. stock, see the HK:6699 Stock Forecast page.

More about Angelalign Technology Inc.

Angelalign Technology Inc. is an orthodontic technology company focused on clear aligner solutions for dental treatment. The group operates internationally with a strong presence in China, leveraging a global sales and service network and clinical support infrastructure to expand into lower-tier markets and early treatment segments.

Average Trading Volume: 555,971

Technical Sentiment Signal: Buy

Current Market Cap: HK$13.1B

For a thorough assessment of 6699 stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1